It is a study done on patients undergoing general anaesthesia to study effect of precurarisation with succinylcholine on succinylcholine induced fasciculations and myalgia. The study is done to assess the efficacy of cisatracurium,rocuronium and placebo

INTERVENTION: Intervention1: nil: nil Control Intervention1: Group 1 ‐ Cisatracurium: Cisatracurium is an intermediate acting nondepolarising skeletal muscle relaxant which blocks nicotinic cholinergic receptors. Cisatracurium 0.01mg/kg (3ml) intravenous is used once. Duration of intervention is 24hours. Control Intervention2: Group 2 ‐ Rocuronium: Rocuronium is an intermediate acting nondepolarising skeletal muscle relaxant which blocks nicotinic cholinergic receptors.Rocuronium 0.06mg/kg (3ml) intravenous is used once.Duration of intervention is 24 hours. Control Intervention3: Group 3 ‐ Normal saline: 3ml of normal saline is used as placebo Control Intervention4: Group 3 ‐ normal saline: 3ml of normal saline is used intravenously for once. Duration of intervention is 24 hours. CONDITION: Health Condition 1: O‐ Medical and Surgical Health Condition 2: M958‐ Other specified acquired deformities of musculoskeletal system PRIMARY OUTCOME: 1.Study the efficacy of cisatracurium and rocuronium pretreatment in preventing ; succinylcholine induced fasciculations. ; 2.Study the efficacy of cisatracurium and rocuronium pretreatment in preventing postoperative myalgia in post‐anesthesia care unit(PACU)Timepoint: 1.Study the efficacy of cisatracurium and rocuronium pretreatment in preventing ; succinylcholine induced fasciculations at baseline. ; 2.Study the efficacy of cisatracurium and rocuronium pretreatment in preventing postoperative myalgia in post‐anesthesia care unit(PACU) for 2 hours. SECONDARY OUTCOME: 1.Study the efficacy of cisatracurium and rocuronium pretreatment in preventing postoperative myalgia at 24hoursTimepoint: From 2 hours post‐operatively till 24hours post‐operatively. INCLUSION CRITERIA: 1.Patients undergoing elective surgery under general anesthesia 2.Patients age between 18‐60 years 3.Patients who fulfill American Society of Anesthesiology category I and II